A dopamine-based radioactive microsphere, its preparation method and applications

By preparing polylactic acid-glycolic acid copolymer microspheres coated with a polydopamine shell and grafting them with tetrazine compounds, the problems of non-degradability and high density of existing radioactive microspheres were solved, enabling effective internal irradiation and click drug delivery for liver cancer and providing a new treatment approach.

CN117547625BActive Publication Date: 2026-11-10WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210942654.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-05
Publication Date
2026-11-10
Estimated Expiration
2042-08-05

AI Technical Summary

Technical Problem

Existing radioactive microspheres for treating liver cancer have limitations due to their non-biodegradability, high density, and difficulty in being formulated into suspension injections, which restricts the application and efficacy of transarterial radioembolization therapy.

Method used

Biodegradable radioactive microspheres were prepared by using polylactic-co-glycolic acid copolymer microspheres coated with a polydopamine shell and grafting tetrazine compounds onto them for radioembolization therapy, while simultaneously achieving localized drug delivery to tumors.

Benefits of technology

This approach achieves effective internal radiation therapy for liver cancer and enables local drug delivery to the tumor simultaneously with radioembolization therapy, providing a new combined treatment strategy and broadening the scope of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117547625B_ABST
    Figure CN117547625B_ABST
Patent Text Reader

Abstract

This invention provides a dopamine-based radioactive microsphere, its preparation method, and its applications, belonging to the field of biomaterials technology. Specifically, it provides a polylactic-co-glycolic acid copolymer microsphere with a polydopamine shell; the polydopamine shell is grafted with a tetrazine compound; the polylactic-co-glycolic acid copolymer microsphere is prepared from polylactic-co-glycolic acid copolymer as raw material through an emulsification crosslinking method; the structure of the tetrazine compound is shown in Formula I. The microspheres of this invention can treat cancer, especially liver cancer, with good results. During embolization therapy, it utilizes a tetrazine click-release reaction to release chemotherapeutic drugs in situ at the tumor site, achieving local click-release of drugs. The microspheres of this invention can effectively inhibit the growth and metastasis of liver tumors, providing a new approach for the combined treatment of liver cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomaterials technology, specifically relating to a dopamine-based radioactive microsphere, its preparation method, and its uses. Background Technology

[0002] Primary hepatic carcinoma is one of the most common malignant tumors worldwide. According to the latest global cancer statistics released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, liver cancer ranks 6th in incidence and 3rd in mortality among all cancers. The mortality rate is higher than the incidence rate, indicating that there is currently no effective treatment for this malignant tumor. For patients in the early stages of liver cancer, the currently accepted clinical treatment options mainly include liver transplantation, surgical resection, and radiofrequency ablation. However, most liver cancer patients are diagnosed at a middle or even late stage, often with invasion of large blood vessels. Without timely and effective treatment, the survival period for these patients is only 2-5 months.

[0003] With the continuous development of medicine, local tumor control therapy has been widely used in the clinical treatment of unresectable intermediate and advanced liver cancer. This mainly includes stereotactic radiotherapy and transarterial radioembolization (TARE) to reduce tumor volume, alleviate symptoms, and create conditions for subsequent tumor resection and living donor liver transplantation. However, normal liver cells are sensitive to radiation. When the radiation dose to the liver area exceeds 40 gray, it can affect the physiological function of normal liver tissue, causing clinicopathological syndromes such as ascites, anicteric hepatomegaly, and elevated liver serum enzymes, resulting in limited efficacy of external beam radiation therapy for liver cancer. Considering these limiting factors, minimally invasive TARE has emerged and is widely used in the treatment of unresectable intermediate and advanced liver cancer. TARE involves injecting a micron-sized embolizing agent loaded with radiotherapy isotopes into the liver cancer tissue via an arterial catheter, achieving effective treatment of liver cancer. The principle behind this treatment is twofold. Firstly, the liver has a dual blood supply: liver cancer cells primarily receive blood from the hepatic artery, while normal liver cells receive approximately 90% blood from the portal vein. TARE therapy, through embolization, blocks the nutrient supply to liver cancer cells, causing ischemia and hypoxia in the tumor tissue and inducing apoptosis. Secondly, it can kill liver cancer cells through the radiation of a radioactive isotope. Yttrium-90 (Yttrium-90) is one such radioactive isotope. 90 Y) is a commonly used radionuclide in this technology.

[0004] Currently, there are two main types in clinical practice. 90 Y-microspheres for transarterial radiotherapy embolization: Resin microspheres ( Sirtex Medical Limited, Australia) and glass microspheres ( Biocompatilbles (UK). Clinical studies have shown that IR-Soheres 90 Y-resin microspheres can slow tumor growth without affecting patients' quality of life, but the resin microspheres exist in the body. 90 The problem of Y nuclide shedding. And... Glass microspheres are the first product to receive FDA approval for TARE therapy, primarily addressing... 90 The problem of radionuclide shedding and in vivo dissolution from Y resin microspheres. However, Glass microspheres also have some drawbacks, mainly in the following aspects: First, glass microspheres are non-biodegradable. Once introduced into the body, they remain permanently in the capillary network of the patient's liver, and can only be removed surgically. Second, the density of glass microspheres is too high, making it difficult to prepare them into a suspension for injection, which causes inconvenience for injection. These factors have limited the clinical promotion of TARE technology to some extent.

[0005] Therefore, the development of novel biodegradable radionuclide microspheres to reduce the treatment cost of TRAE and broaden the application scope of this treatment technology has received widespread attention from researchers and clinicians. Summary of the Invention

[0006] The purpose of this invention is to provide a dopamine-based radioactive microsphere, its preparation method, and its uses.

[0007] This invention provides a microsphere, which is a polylactic-co-glycolic acid copolymer microsphere with a polydopamine shell on its surface; the polydopamine shell is grafted with a tetrazine compound;

[0008] The polylactic acid-glycolic acid copolymer microspheres are prepared by using polylactic acid-glycolic acid copolymer as raw material through an emulsification crosslinking method;

[0009] The structure of the tetrazine compound is shown in Formula I:

[0010]

[0011] in,

[0012] n is an integer selected from 0 to 10;

[0013] R1 is selected from substituted or unsubstituted 6-10 aryl groups. Therefore, the substituents of the aryl group are selected from I, 131 I,

[0014] a is an integer selected from 0 to 3;

[0015] R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements;

[0016] R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively.

[0017] R2 is selected from hydrogen, C1-C8 alkyl, tert-butoxycarbonyl, ...

[0018] b is an integer selected from 1 to 8;

[0019] R8 is selected from hydrogen, C1-C8 alkyl, and tert-butoxycarbonyl.

[0020] Furthermore,

[0021] n is an integer selected from 0 to 3;

[0022] R1 is selected from substituted or unsubstituted phenyl groups. Therefore, the substituents of the phenyl group are selected from I, 131 I,

[0023] a is an integer selected from 0 to 3;

[0024] R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements;

[0025] R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively.

[0026] R2 is selected from hydrogen, C1-C8 alkyl, tert-butoxycarbonyl, ...

[0027] b is an integer selected from 1 to 5;

[0028] R8 is selected from hydrogen, C1-C8 alkyl, and tert-butoxycarbonyl.

[0029] Furthermore, the structure of the tetrazine compound is shown in Formula II:

[0030]

[0031] in,

[0032] n is an integer selected from 0 to 3;

[0033] R1 is selected from substituted or unsubstituted phenyl groups. Therefore, the substituents of the phenyl group are selected from I, 131 I,

[0034] a is an integer selected from 0 to 3;

[0035] R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements;

[0036] R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively.

[0037] b is an integer selected from 1 to 5;

[0038] R8 is selected from hydrogen, C1-C8 alkyl, and tert-butoxycarbonyl;

[0039] Preferably, the structure of the tetrazine compound is shown in Formula III:

[0040]

[0041] in,

[0042] n is an integer selected from 0 to 3;

[0043] R9 is selected from hydrogen, I, 131 I,

[0044] R4 is selected from The The radioactive element may or may not be chelated; the radioactive element is gallium-68 or yttrium-90.

[0045] R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively.

[0046] b is an integer selected from 1 to 5;

[0047] R8 is selected from hydrogen, C1-C8 alkyl, and tert-butoxycarbonyl;

[0048] Alternatively, the structure of the tetrazine compound is shown in Formula IV:

[0049]

[0050] in,

[0051] a is an integer selected from 0 to 3;

[0052] n is an integer selected from 0 to 3;

[0053] b is an integer selected from 1 to 5;

[0054] The compound shown in Formula IV may or may not chelate a radioactive element; the radioactive element is gallium-68 or yttrium-90.

[0055] Alternatively, the structure of the tetrazine compound is shown in Formula V:

[0056]

[0057] in

[0058] n is an integer selected from 0 to 3;

[0059] b is an integer selected from 1 to 5;

[0060] The compound shown in Formula V may or may not chelate a radioactive element; the radioactive element is gallium-68 or yttrium-90.

[0061] More preferably, the structure of the tetrazine compound is shown in Formula VI:

[0062]

[0063] in

[0064] b is an integer from 1 to 5.

[0065] Furthermore, the structure of the tetrazine compound is one of the following compounds:

[0066]

[0067]

[0068] Furthermore, the polylactic acid glycolate copolymer is a polylactic acid glycolate copolymer with GA:LA = 75:25 and MW: 4000-15000.

[0069] Furthermore, the preparation method of the polylactic acid glycolic acid copolymer microspheres coated with a polydopamine shell includes the following steps: reacting the polylactic acid glycolic acid copolymer microspheres with dopamine in a solvent to obtain the product;

[0070] Preferably,

[0071] The mass ratio of the polylactic acid-glycolic acid copolymer microspheres to dopamine is 1:(1-4);

[0072] And / or, the solvent is a Tris-HCl aqueous solution;

[0073] And / or, the reaction is carried out at room temperature with stirring at 100-1000 rpm for 1-5 hours;

[0074] More preferably, the mass ratio of the polylactic acid-glycolic acid copolymer microspheres to dopamine is 1:2;

[0075] And / or, the concentration of the Tris-HCl aqueous solution is 10 mM and the pH is 8-9;

[0076] And / or, the reaction is carried out at room temperature with stirring at 500 rpm for 1 h;

[0077] And / or, the reaction is purified, and the purification method is to centrifuge the reaction solution, discard the supernatant, wash, and freeze-dry.

[0078] Furthermore, the preparation method of the polylactic acid-glycolic acid copolymer microspheres includes the following steps:

[0079] (1) Dissolve the polylactic acid-glycolic acid copolymer in an organic solvent to obtain an organic solution of the polylactic acid-glycolic acid copolymer;

[0080] (2) Dissolve the crosslinking agent in an aqueous solution to obtain a crosslinking agent solution;

[0081] (3) Add the polylactic acid-glycolic acid copolymer organic solution dropwise to the crosslinking agent solution, stir and react to obtain the product;

[0082] Preferably,

[0083] In step (1), the organic solvent is DCM;

[0084] And / or, in step (1), the concentration of the polylactic acid-glycolic acid copolymer organic solution is 1-5%;

[0085] And / or, in step (2), the crosslinking agent is polyvinyl alcohol;

[0086] And / or, in step (2), the concentration of the crosslinking agent solution is 0.4 to 1.0%;

[0087] And / or, in step (3), the crosslinking agent solution is stirred during the dropwise addition.

[0088] And / or, in step (3), the reaction temperature is room temperature;

[0089] And / or, in step (3), the reaction is purified by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

[0090] Furthermore, the method for attaching tetrazine compounds to the polydopamine shell includes the following steps:

[0091] 1) Dissolve PLGA@PDA microspheres in water to obtain a PLGA@PDA microsphere suspension;

[0092] 2) Dissolve tetrazine compounds in water to obtain tetrazine aqueous solutions;

[0093] 3) Add the tetrazine aqueous solution to the PLGA@PDA microsphere suspension and react to obtain the product; the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:(1-5);

[0094] Preferably,

[0095] In step 3), the pH of the reaction solution is 9-10 during the reaction.

[0096] And / or, in step 3), the reaction is carried out at room temperature for 10–20 h;

[0097] And / or, in step 3), the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:2;

[0098] And / or, in step 3), the reaction is purified by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

[0099] The present invention also provides a method for preparing the aforementioned microspheres, comprising the following steps:

[0100] 1) Dissolve PLGA@PDA microspheres in water to obtain a PLGA@PDA microsphere suspension;

[0101] 2) Dissolve tetrazine compounds in water to obtain tetrazine aqueous solutions;

[0102] 3) Add the tetrazine aqueous solution to the PLGA@PDA microsphere suspension and react to obtain the product; the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:(1-5);

[0103] Preferably,

[0104] In step 3), the pH of the reaction solution is 9-10 during the reaction.

[0105] And / or, in step 3), the reaction is carried out at room temperature for 10–20 h;

[0106] And / or, in step 3), the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:2;

[0107] And / or, in step 3), the reaction is purified by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

[0108] The present invention also provides the use of the aforementioned microspheres in the preparation of medicaments for treating cancer;

[0109] Preferably, the cancer is liver cancer;

[0110] More preferably, the liver cancer is primary liver cancer.

[0111] The present invention also provides a mitomycin C prodrug, the structure of which is shown below:

[0112]

[0113] The present invention also provides the use of the aforementioned microspheres in combination with the aforementioned mitomycin C prodrug in the preparation of a medicament for treating cancer;

[0114] Preferably, the cancer is liver cancer;

[0115] More preferably, the liver cancer is primary liver cancer.

[0116] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0117] This invention provides biodegradable PLGA@PDA microspheres grafted with tetrazine compounds, which can treat cancer, particularly liver cancer. When the tetrazine compounds on the microspheres contain radioactive elements, they can be used for radioembolization therapy, achieving internal radiation therapy for liver cancer. Furthermore, the tetrazine compounds grafted onto the microspheres can simultaneously perform radioembolization therapy and utilize a click-release reaction to release chemotherapeutic drugs in situ from the tumor, achieving local click-release of drugs. The microspheres of this invention can organically combine internal radiation therapy and click-release, effectively inhibiting the growth and metastasis of liver tumors, providing a new approach for the combined treatment of liver cancer, and have broad application prospects.

[0118] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.

[0119] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description

[0120] Figure 1 Characterization results of PLGA microspheres: a) Particle size distribution of PLGA microspheres prepared from PLGA polymers with GA:LA = 75:25 and MW: 4000-15000; b) Particle size distribution of PLGA microspheres prepared from PLGA polymers with GA:LA = 50:50 and MW: 50000-115000; c) Electron microscopy results of microspheres prepared from low molecular weight (MW: 4000-15000) PLGA; d) Electron microscopy results of microspheres prepared from high molecular weight (MW: 50000-115000) PLGA.

[0121] Figure 2Scanning electron microscope images of PLGA@PDA microspheres prepared with different PLGA microsphere to DA feed ratios. The scale of the microspheres prepared with each feed ratio is the same as that of PLGA∶DA=1∶1.

[0122] Figure 3 The elemental characterization results of PLGA microspheres coated with PDA are as follows: a) XPS spectra of PLGA@PDA microspheres prepared with PLGA microsphere:DA feed ratios of 1:1, 1:2, 1:3, and 1:4; b) XPS spectra of PLGA microspheres; c) Statistical analysis of nitrogen content in microspheres prepared with different PLGA to DA feed ratios.

[0123] Figure 4 The solution condition of microspheres prepared by using different feed ratios of PLGA microspheres and DA after 1 week.

[0124] Figure 5 Characterization results of PLGA@PDA microspheres: a) EDS scan results of PLGA microspheres and PLGA@PDA microspheres; b) N element spectrum of each layer of PLGA@PDA microspheres obtained by XPS depth analysis; c) Statistical chart of N element percentage content of each layer of PLGA@PDA microspheres obtained by XPS depth analysis; d) Statistical chart of particle size distribution of PLGA@PDA microspheres.

[0125] Figure 6 Results of the study on the modification of PLGA@PDA-Tz-I microspheres with tetrazine small molecules: a) XPS characterization results of microspheres prepared with different tetrazine molecules; b) Statistical results of iodine content on the surface of microspheres prepared with different tetrazine molecules; c) EDS scan image of PLGA@PDA-Tz-I microspheres prepared with Tz2.

[0126] Figure 7 Fluorescence imaging results of PLGA@PDA-Tz-I microspheres: a) Fluorescence image of PLGA@PDA microspheres after reaction with TCO-Cy5.5; b) Fluorescence image of PLGA@PDA-Tz-I microspheres after reaction with TCO-Cy5.5.

[0127] Figure 8 The results of in vitro degradation studies of PLGA@PDA-Tz-I microspheres.

[0128] Figure 9 The top image shows the HPLC chromatograms before and after the radiolabeling experiment with gallium-68; the bottom image shows the HPLC results of the labeled gallium-68 detected by the radiodetector; the bottom image shows the HPLC chromatogram of the unlabeled compound under the same conditions.

[0129] Figure 10 This is the γ-HPLC chromatogram of compound 17.

[0130] Figure 11 The image shows a cross-section of PLGA@PDA-Tz-I microspheres embolizing liver vessels; a) shows the distribution of microspheres 7 days after liver embolization; b) shows the distribution of microspheres 30 days after liver embolization; the red box contains the embolized microspheres.

[0131] Figure 12 For PLGA@PDA-Tz- 131 Results of in vivo stability study of I-microsphere radioactive iodine-131: a is PLGA@PDA-Tz- 131 I is microspheres; b is Na 131 I. Long-term SPECT / CT fusion imaging in vivo.

[0132] Figure 13 For PLGA@PDA-Tz- 131 Research on the use of I-microspheres in the treatment of liver cancer. MRI scan images of each experimental group at different time points. Note: The area within the red dotted line represents the tumor region; Group A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, group B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I; Group E: TCO-Mitomycin C prodrug group; Group F: Sham surgery group.

[0133] Figure 14 The trend of tumor volume changes in each group over time. A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I; Group E: TCO-Mitomycin C prodrug group; Group F: Sham surgery group.

[0134] Figure 15 The survival time of rats in each experimental group is statistically analyzed. A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I treatment group; Group E: TCO-Mitomycin C prodrug group; Group F: Sham surgery group.

[0135] Figure 16 For PLGA@PDA-Tz- 131 The effect of microsphere embolization on liver function in rats. Detection of ALT and AST levels in serum of rats in each experimental group. A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I treatment group; Group E: TCO-Mitomycin C prodrug group; Group F: Sham surgery group.

[0136] Figure 17 The results of H&E staining of major organs in each group. A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I; Group E: TCO-Mitomycin C prodrug group; Group F: Sham surgery group. Detailed Implementation

[0137] Unless otherwise stated, the raw materials and equipment used in the specific embodiments of the present invention are all known products and were obtained by purchasing commercially available products.

[0138] The SMMC-7721 and HepG2 cells used in this invention were cultured in DMEM medium containing 10% fetal bovine serum (FBS), and all cells were cultured at 37°C and 5% CO2. The experimental animals used in this invention were female SD rats (6 weeks old, weighing 250-300g) living under specific pathogen-free conditions at the Animal Center of West China Clinical Science and Technology Park, Sichuan University.

[0139] Statistical analysis

[0140] Statistical analysis of the data was performed using unpaired t-tests. All experimental data are expressed as mean ± standard error (Mean ± SEM), and a p-value < 0.05 was considered statistically significant. All statistical analyses of the results were conducted using GraphPad Prism 7 software.

[0141] Example 1: Synthesis of small molecule tetrazine and prodrug

[0142] (1) Synthesis of compound 6

[0143]

[0144] Weigh 1.00 g of 4-iodocyanobenzene (5.88 mmol), 3.30 g of N-(2-cyanoethyl)carbamate tert-butyl ester (14.41 mmol), and 632.0 mg of nickel trifluoromethanesulfonate (1.93 mmol) into a 25 mL round-bottom flask. Dissolve the reactants in 2.0 mL of ethanol. Slowly add 4.0 mL of 98% hydrazine hydrate to the reaction flask under ice bath conditions. Remove the ice bath and heat and stir in a constant temperature oil bath at 60 °C overnight. Monitor the reaction of the starting materials by TLC until complete. Weigh 4.46 g of NaNO2 and dissolve it in 100 mL of water. Add the reaction solution to approximately 50 mL of DCM. Under ice bath conditions, add the reaction solution dropwise to the NaNO2 aqueous solution. Add 1 M HCl solution dropwise to adjust the pH of the solution to 3-4. Then extract three times with DCM, wash once with saturated NaCl solution, dry with anhydrous Na2SO4, and filter. The reaction mixture was evaporated to dryness and then purified by rapid normal-phase silica gel column chromatography; a total of 600.0 mg of red solid product 6 was obtained, with a yield of 23.9%; compound characterization data: 1 H NMR (400MHz, DMSO-d6) δ 8.30-8.20 (m, 2H), 8.10-8.01 (m, 2H), 3.48 (q, J=6.2Hz, 2H), 3.38 (dd, J=6.9, 5.3Hz, 2H), 1.26 (s, 9H). 13 C NMR (151MHz, DMSO-d6) δ168.53, 163.52, 156.03, 138.90, 131.83, 129.51, 101.15, 78.23, 35.98, 28.58.

[0145] (2) Synthesis of compound 7

[0146]

[0147] Compound 6, weighed 600.0 mg (1.41 mmol), was dissolved in 4.0 mL of dichloromethane, followed by the addition of 1 mL of TFA. The reaction was carried out at room temperature for 1 h, and TLC was used to monitor the reaction completion. The reaction mixture was concentrated and then purified by rapid normal-phase silica gel column chromatography; a total of 428.0 mg of red solid product 7 was obtained, with a yield of 93.0%. Compound characterization data: 1 H NMR (400MHz, DMSO-d6) δ8.27 (d, J=8.5Hz, 2H), 8.09 (d, J=8.5Hz, 2H), 7.99 (s, 2H), 3.65 (t, J=6.9Hz, 2H), 3.46 (t, J=6.9Hz, 2H). 13C NMR (151MHz, DMSO-d6) δ166.83, 163.40, 138.54, 138.54, 131.23, 129.16, 129.16, 100.98, 36.87, 32.23.HRMS (ESI) m / z calcd forC 10 H 10 IN5 + (M+H) + 328.0054, found 328.0060.

[0148] (3) Synthesis of compound 8

[0149]

[0150] 7200.0 mg (0.61 mmol) of compound and 380.0 mg (0.79 mmol) of 2,5-dioxapyrrolidone-1-yl 3-((((((9H-fluorene-9-yl)methoxy)carbonyl)amino)methoxy)propionate were weighed and dissolved in 14 mL of anhydrous DCM. 380.0 mg (3.17 mmol) of TEA was added dropwise with stirring at room temperature. The reaction was stirred at room temperature and monitored by TLC. The reactants were completely reacted after 2.5 h. The reaction mixture was concentrated and then purified by rapid normal-phase silica gel column chromatography. A total of 296.0 mg of red solid product 8 was obtained, with a yield of 70.0%. 1 HNMR (400MHz, Chloroform-d) δ8.28 (d, J=8.2Hz, 2H), 7.94 (d, J=8.5Hz, 2H), 7.71 (d, J=7.6Hz, 2H), 7.57 (d, J=7.5Hz, 2H), 7.44-7. 31 (m, 4H), 5.49 (s, 1H), 4.46 (d, J = 6.5Hz, 2H), 4.19 (t, J = 6.4Hz, 1H), 4.00-3.88 (m, 4H), 3.65-3.49 (m, 8H), 3.43 (d, J = 5.8Hz, 2H).

[0151] (4) Synthesis of compound 9

[0152]

[0153] 853.2 mg (0.08 mmol) of the compound was weighed, and 1 mL of DCM was added to dissolve the starting material. Then, 0.5 mL of EDA was added, and the mixture was stirred at room temperature. The reaction was monitored by TCL, and the reaction was completed in 4 hours. The reaction mixture was then concentrated and purified by rapid normal-phase silica gel column chromatography to obtain 30.2 mg of red solid product 9, with a yield of 92.5%. HRMS (ESI) m / z calcd for C 17 H24 IN6O3 + (M+H) + 487.0949, found 487.0946.

[0154] (5) Synthesis of compound 10

[0155]

[0156] 7150.0 mg (0.46 mmol) of compound and 200.0 mg (0.39 mmol) of BOC-amino-pentaethylene glycol-NHS ester (Fmoc-NH-PEG5-NHS) were weighed into a 25 mL round-bottom flask, dissolved in 10 mL of dichloromethane, followed by the addition of 185 mg (1.85 mmol) of TEA. The reaction was carried out at room temperature. The reaction was monitored by TLC and completed in approximately 3 hours. The reaction mixture was directly concentrated and then purified by rapid normal-phase silica gel column chromatography; a total of 198.0 mg of red solid product was obtained, with a yield of 85.3%. Compound characterization data: 1 H NMR (400MHz, Chloroform-d) δ8.39-8.25(m, 2H), 8.04-7.86(m, 2H), 7.15(s, 1H), 5.14(s, 1H), 3.88(q , J=6.3Hz, 2H), 3.74-3.49 (m, 23H), 3.31 (q, J=5.4Hz, 2H), 2.43 (td, J=5.7, 2.3Hz, 2H), 1.43 (s, 10H). 13 C NMR (101MHz, Chloroform-d) δ172.18, 172.14, 168.43, 163.99, 156.06, 138.61, 131.33, 129.33, 100.31, 70.55, 70.51, 70.48, 7 0.40, 70.32, 70.27, 70.19, 70.09, 67.13, 67.09, 40.37, 37.35, 36.79, 35.02, 29.70, 28.44, 25.42, 22.70, 14.13.HRMS (ESI) m / z calcd for C 28 H 44 IN6O8 + (M+H) + 719.2260, found 719.2280.

[0157] (6) Synthesis of compound 11

[0158]

[0159] 10194.0 mg (0.23 mmol) of compound was weighed into a 25 mL round-bottom flask, dissolved in 3.0 mL of dichloromethane, and then 1.5 mL of TFA was added. The reaction was carried out at room temperature. The reaction was monitored by TLC and completed in approximately 3 hours. The reaction mixture was directly concentrated and then purified by rapid normal-phase silica gel column chromatography; 155.0 mg of red solid product 11 was obtained, with a yield of 93.0%. Compound characterization data: 1 H NMR(400 MHz, Chloroform-d) δ8.52 (t, J=5.6Hz, 1H), 8.30 (d, J=8.6Hz, 2H), 7.93 (d, J=8.6H z, 2H), 3.99-3.92 (m, 2H), 3.86 (q, J=6.5Hz, 2H), 3.80-3.76 (m, 2H), 3.73 (d, J=6.0H z, 1H), 3.70 (dd, J=5.8, 3.0Hz, 4H), 3.64 (d, J=5.4Hz, 5H), 3.61-3.57 (m, 5H), 3.48 (s, 1H), 3.14-3.06 (m, 2H), 2.61 (t, J=6.0Hz, 2H), 1.32-1.23 (m, 4H).HRMS (ESI) m / z calcd for C 23 H 36 IN6O6 + (M+H) + 619.1736, found 619.1783.

[0160] (7) Synthesis of compound 12

[0161]

[0162] 250.0 mg (0.77 mmol) of compound 7 and 433.0 mg (0.68 mmol) of BOC-amino-octaethylene glycol-NHS ester (Boc-NH-PEG8-NHS, 0.68 mmol) were weighed into a 50 mL round-bottom flask, dissolved in 15 mL of dichloromethane, followed by the addition of 309.0 mg of TEA. The reaction was carried out at room temperature. The reaction was monitored by TLC and completed in 3 h. The reaction was concentrated and then purified by rapid normal-phase silica gel column chromatography; a total of 445.6 mg of red solid product 12 was obtained, with a yield of 74.0%. Compound characterization data: 1HNMR (400MHz, Chloroform-d) δ8.48-8.21 (m, 2H), 8.07-7.87 (m, 2H), 7.16 (s, 1H), 5.15 (s, 1H), 3.8 8 (q, J=6.2Hz, 2H), 3.72-3.50 (m, 39H), 3.31 (q, J=5.4Hz, 2H), 2.43 (t, J=5.7Hz, 2H), 1.44 (s, 10H). 13 C NMR (151MHz, DMSO-d6) δ170.77, 168.47, 163.63, 156.03, 138.92, 131.87, 129.57, 7 8.03, 70.25, 70.22, 70.10, 69.98, 69.96, 69.64, 67.14, 37.55, 36.59, 35.29, 28.70. 13 C NMR (151MHz, DMSO-d6) δ170.77, 168.47, 163.63, 156.03, 138.92, 131.87, 129.57, 7 8.03, 70.25, 70.22, 70.10, 69.98, 69.96, 69.64, 67.14, 37.55, 36.59, 35.29, 28.70.

[0163] (8) Synthesis of compound 13

[0164]

[0165] The obtained compound 12222.5 mg (0.25 mmol) was placed in a 25 mL round-bottom flask, dissolved in 5 mL of dichloromethane, and then 1.3 mL of TFA was added. The reaction was carried out at room temperature. The reaction was monitored by TLC, and the reaction was completed in 2 h. The reaction was directly concentrated and then purified by rapid normal-phase silica gel column chromatography; 178.0 mg of red solid product 13 was obtained, with a yield of 90.0%. Compound characterization data: 1 H NMR (400MHz, Chloroform-d) δ8.30 (d, J=8.5Hz, 2H), 8.03-7.95 (m, 1H), 7.93 (d, J=8.5Hz, 2H), 3.86 (q, J=6.3H z, 4H), 3.76-3.55 (m, 32H), 3.20 (t, J = 4.9Hz, 2H), 2.52 (t, J = 6.1Hz, 2H), 1.26 (d, J = 12.9Hz, 2H). HRMS (ESI) m / z calcd forC 29 H 48 IN6O9 + (M+H)+ 751.2522, found 751.2528.

[0166] (9) Synthesis of compound 14

[0167]

[0168] 2.0 mg (0.19 mmol) of compound 1014, 46.0 mg (0.040 mmol) of tetraphenylphosphine palladium, and 50.0 mg of lithium chloride were weighed and dissolved in 5.0 mL of toluene. Then, 84.0 mg (0.26 mmol) of hexamethyldistin was added. Under nitrogen protection, the reaction was carried out at 100 °C for 3 h. TLC showed that the starting material had basically reacted completely. Subsequent reaction processing: diatomaceous earth filtration, washing twice with DCM, direct concentration, and then purification by rapid normal-phase silica gel column chromatography were performed to obtain a dark reddish-brown solid product 14, totaling 37.3 mg, with a yield of 30.1%. Characterization data: 1 H NMR (400MHz, Chloroform-d) δ 8.57-8.44 (m, 2H), 7.82-7.62 (m, 2H), 7.14 (s, 1H), 5.17 (s, 1H), 3.90 (q, J=6.3Hz, 2H), 3.69 ( t, J=5.7Hz, 2H), 3.65-3.55 (m, 19H), 3.53 (t, J=5.1Hz, 2H), 3.49 (s, 1H), 3.30 (d, J=5.3Hz, 2H), 1.43 (s, 10H), 0.36 (s, 9H).

[0169] A total of 37.3 mg of tetrazine precursor compound 14 for iodine-131 labeling was prepared by a four-step reaction, with an overall yield of 5.8%.

[0170] (10) Synthesis of compound 15

[0171]

[0172] Compound 12150.0 mg (0.18 mmol), tetra(triphenylphosphine)palladium 41.4 mg (0.03 mmol), and lithium chloride 44.4 mg were weighed and dissolved in 5.0 mL of toluene. Then, hexamethyldistin 74.7 mg (0.23 mmol) was added. Under nitrogen protection, the reaction was carried out at 100 °C for 3 h. TLC (DCM:MeOH = 10:1, v / v) showed that the reactants were basically completely reacted. Subsequent reaction processing: diatomaceous earth filtration, washing twice with DCM, direct concentration, and then purification by rapid normal-phase silica gel column chromatography were performed to obtain a dark reddish-brown solid product 15, totaling 66.9 mg, with a yield of 51.0%. Characterization data of trimethyltin phenyltetraazine-PEG8-NH-Boc: 1H NMR (400MHz, Chloroform-d) δ8.55-8.48 (m, 2H), 7.76-7.70 (m, 2H), 7.13 (s, 1H), 5.13 (s, 1H), 3.89 (q, J= 6.3Hz, 2H), 3.73-3.48 (m, 37H), 3.31 (d, J=6.0Hz, 2H), 2.44 (t, J=5.7Hz, 2H), 1.44 (s, 11H), 0.36 (s, 9H).

[0173] (11) Synthesis of compound 16

[0174]

[0175] 10.0 mg (0.03 mmol) of mitomycin C and 7 mg (0.02 mmol) of (2E)-TCO-PNB ester were weighed and dissolved in 500 μL of anhydrous DMF. Then, 9.4 mg (0.09 mmol) of TEA and 3.6 mg (0.03 mmol) of DMAP were added. The reaction was carried out at room temperature for 15 h. TCL monitoring showed that the starting material was basically completely reacted. Subsequent processing was performed: washing once with water, extraction twice with EA, collection of the organic phase, washing once with saturated NaCl, drying and filtering with anhydrous NaSO4, and purifying by rapid normal-phase silica gel column chromatography after rotary evaporation. A total of 7.45 mg of dark blue solid product 16 was obtained, with a yield of 64.2%. Compound characterization data: 1 H NMR (400MHz, Chloroform-d) δ5.86-5.71 (m, 1H), 5.52-5.44 (m, 1H), 5.32 (d, J=11.5Hz, 1H), 5.25 (s, 1H), 5.07 (m, J=41.4, 11.0, 4.8Hz, 1H), 4.74 (d, J=9.7Hz, 1H), 4.48 (dd, J=13.3, 4.7Hz, 1H), 4.30 (td, J=10.8, 9.2Hz, 1H), 4.12 ( d, J=7.2Hz, 1H), 3.71 (m, J=10.7, 7.2, 4.8Hz, 1H), 3.51-3.46 (m, 1H), 3.32 (s, 1H), 3.19 (s, 3H), 2.45 (dd, J=10.0, 4 .9Hz, 1H), 2.04 (s, 3H), 1.88 (d, J=6.0Hz, 1H), 1.77 (d, J=2.5Hz, 2H), 1.65 (t, J=6.0Hz, 4H), 1.25 (t, J=7.1Hz, 4H). 13C NMR (151MHz, DMSO-d6) δ177.17, 176.32, 176.27, 160.15, 159.99, 156.81, 156.79, 155.05, 149. 27, 149.21, 132.53, 131.89, 131.24, 130.69, 110.14, 106.29, 106.13, 103.39, 103.36, 76.02, 7 5.93, 60.60, 60.40, 55.38, 49.82, 49.78, 49.06, 43.62, 42.55, 42.50, 40.91, 35.90, 35.79, 35. 71, 35.60, 28.80, 28.74, 28.74, 27.07, 25.57, 24.00, 23.83, 22.56, 14.42, 8.83.HRMS(ESI)m / z calcd for C 24 H 30 N4NaO7 + (M+Na) + 509.2012, found 509.2010.

[0176] The TCO-Mitomycin C prodrug was synthesized in a one-step reaction with a yield of 64.2%.

[0177] (12) Synthesis of compounds 19 and 20

[0178]

[0179] Weigh 500 mg of 4-cyanobenzoic acid (3.40 mmol), 4.60 g of N-(2-cyanoethyl)carbamate tert-butyl ester (27.06 mmol), and 360.0 mg of mercaptopropionic acid (3.39 mmol) into a 25 mL round-bottom flask. Dissolve the reactants in 5.0 mL of DMSO. Slowly add 10.0 mL of 80% hydrazine hydrate to the reaction flask in an ice bath at 0 °C. Remove the ice bath and stir overnight at room temperature. Monitor the reaction progress by TLC. Weigh 4.2 g of NaNO₂ and dissolve it in 100 mL of water. Add the reaction mixture to the NaNO₂ aqueous solution and add 1 M HCl solution to adjust the pH to 3-4. Extract three times with DCM, wash once with saturated NaCl solution, dry over anhydrous Na₂SO₄, and filter. Reduce the reaction mixture to dryness and then purify using a rapid normal-phase silica gel column chromatography. Obtain 20 g of red solid product (117 mg total), yield 10%. Compound characterization data: 1H NMR (400MHz, MeOD) δ=8.64 (d, J=8.4, 2H), 8.24 (d, J=8.5, 2H), 3.62 (t, J=6.2, 2H), 3.49 (t, J=6.1, 2H), 1.30 (s, 9H). 13 C NMR (101MHz, DMSO) δ168.59, 167.34, 163.41, 156.07, 135.57, 130.68, 127.96, 78.25, 39.25, 36.00, 28.57.

[0180] Additionally, another red solid product, product 19, totaling 577.0 mg, was obtained by rapid forward silica column purification. Compound characterization data: 1 H NMR (400MHz, CDCl3) δ=5.05 (s, 2H), 3.73 (dd, J=12.3, 6.2, 4H), 3.54-3.47 (m, 4H), 1.38 (s, 18H). 13 C NMR (101MHz, CDCl3) δ=168.56, 155.93, 79.68, 38.53, 35.66, 28.46.

[0181] (13) Synthesis of compound 21

[0182]

[0183] 50.0 mg (0.15 mmol) of compound 20 was weighed into a reaction flask, dissolved in 2.0 mL of dichloromethane, and then 0.5 mL of TFA was added. The reaction was carried out at room temperature for 2 h, and TLC was used to monitor the completion of the reaction. The reaction solution was concentrated, dried under vacuum, and used directly in the next step without purification. 20 mg (0.08 mmol) of the previous compound and 41.0 mg (0.08 mmol) of BOC-amino-pentaethylene glycol-NHS ester (Boc-NH-PEG5-NHS) were placed in a 10 mL round-bottom flask, dissolved in 3 mL of acetonitrile and 1 mL of H2O, and then 24.8 mg (0.24 mmol) of TEA was added. The reaction was carried out at room temperature. TLC was used to monitor the completion of the reaction in 2.5 h. The reaction solution was directly concentrated and then purified by rapid normal-phase silica gel column chromatography; 35.0 mg of red oily product 21 was obtained, with a yield of 67%. Compound characterization data: 1H NMR (400MHz, MeOD) δ=8.60 (d, J=8.4, 2H), 8.20 (d, J=8.4, 2H), 3.83 (t, J=6.4, 2H), 3.67-3. 53 (m, 20H), 3.49 (dd, J=7.9, 3.1, 2H), 3.21 (t, J=5.6, 2H), 2.38 (t, J=6.0, 2H), 1.42 (s, 9H). 13 C NMR (101MHz, MeOD) δ=174.36, 172.05, 169.59, 165.38, 158.49, 135.87, 131.24, 128.58 , 80.08, 71.47, 71.43, 71.39, 71.22, 71.17, 68.08, 41.25, 38.75, 37.46, 35.95, 28.77.

[0184] (14) Synthesis of compound 22

[0185]

[0186] Compound 217.2 mg (0.01 mmol), DOTA-tri-tert-butyl-C2-amino 6.9 mg (0.01 mmol), HOBT 2.3 mg (0.02 mmol), and EDCI 3.2 mg (0.02 mmol) were placed in a 10 mL round-bottom flask under argon protection and dissolved in 1 mL of dichloromethane. Then, triethylamine 3.4 mg (0.03 mmol) was added, and the mixture was reacted at room temperature for 24 h. The reaction was monitored by TLC until complete. The reaction solution was directly concentrated and then purified by rapid normal-phase silica gel column chromatography. A total of 6.8 mg of the red product 22 was obtained, with a yield of 49%. Compound characterization data: 1 H NMR (400MHz, CDCl3) δ=8.65 (d, J=8.6, 2H), 8.13 (d, J=8.6, 2H), 3.88 (dd, J= 12.1, 6.3, 2H), 3.68-3.47(m, 20H), 3.36-1.96(m, 34H), 1.48-1.38(m, 36H).

[0187] (15) Synthesis of compound 23

[0188]

[0189] 223.4 mg of compound was placed in a reaction tube and dissolved in 0.6 mL of dichloromethane. Then, 0.2 mL of trifluoroacetic acid was added dropwise. After the addition was complete, the reaction was allowed to proceed at room temperature. The reaction was monitored by HPLC, and the reaction was completed after 12 h. 2.2 mg of compound 23 was obtained, with a liquid phase yield of 86% and a mass spectrometry molecular weight (M+H). +It is 965.6.

[0190] (16) Synthesis of compound 24

[0191]

[0192] 50.0 mg (0.14 mmol) of compound 19 was weighed into a reaction flask, dissolved in 2.0 mL of dichloromethane, and then 0.5 mL of TFA was added. The reaction was carried out at room temperature for 2 h, and TLC was used to monitor the completion of the reaction. The reaction solution was concentrated, dried under vacuum, and used directly in the next step without purification. 15 mg (0.08 mmol) of the previous compound and 41.0 mg (0.09 mmol) of BOC-amino-pentaethylene glycol-NHS ester (Boc-NH-PEG5-NHS) were placed in a 10 mL round-bottom flask, dissolved in 3 mL of acetonitrile and 1 mL of H2O, and then 27.1 mg (0.27 mmol) of TEA was added. The reaction was carried out at room temperature. TLC was used to monitor the completion of the reaction in 4 h. The reaction solution was concentrated directly and then purified by rapid normal-phase silica gel column chromatography; 21.0 mg of red oily product 24 was obtained, with a yield of 51%. Compound characterization data: 1 H NMR (400MHz, CDCl3) δ7.98 (s, 1H), 5.38 (s, 2H), 3.77-3.72 (m, 2H), 3.71-3.51 (m, 26H), 3.30 (d, J=4.7Hz, 2H), 2.37 (t, J=5.5Hz, 2H), 1.43 (s, 9H). 13 CNMR (101MHz, CDCl3) δ173.11, 168.61, 166.73, 156.42, 79.37, 70.56, 70.38, 70. 34, 70.15, 69.83, 69.44, 67.57, 38.40, 38.36, 36.55, 35.22, 33.09, 32.06, 28.57.

[0193] (17) Synthesis of compound 25

[0194]

[0195] 242.8 mg (0.005 mmol) of the compound and 2.5 mg (0.005 mmol) of cyclopentadienetetraacetic acid were placed in a reaction tube, dissolved in 0.5 mL of acetonitrile and 0.2 mL of water, followed by the addition of 1 drop of triethylamine. The reaction was allowed to proceed at room temperature, and the reaction was monitored by HPLC. The reaction was complete after 2 h. 253.5 mg of the compound was obtained with a HPLC yield of 78%, and the molecular weight (M+H) was determined by mass spectrometry. + It is 946.5.

[0196] Example 2: Preparation and Characterization of PLGA Microspheres

[0197] PLGA microspheres were prepared using polylactic-co-glycolic acid copolymer (PLGA) as raw material and polyvinyl alcohol (PVA) as crosslinking agent via an emulsion crosslinking method. The specific operation steps are as follows:

[0198] (1) Solution preparation: ① Weigh 50.0 mg PLGA (GA∶LA=75∶25, MW: 4000-15000; or GA∶LA=50∶50, MW: 50000-115000) and dissolve it in 1.2 mL of DCM; ② Weigh 83.0 mg PVA-203 (MW: ~31000) into a 500 mL round-bottom flask, add 8.0 mL of deionized water, and heat in a 60 °C water bath until completely dissolved to prepare a 1.0% PVA aqueous solution; at the same time, prepare a 0.4% PVA aqueous solution for later use.

[0199] (2) Stir the 1.0% PVA aqueous solution at 1500 rpm and slowly add the DCM solution of PLGA to the 1.0% PVA aqueous solution using a 2.5 mL syringe for about 2-3 minutes.

[0200] (3) Stir the reaction at room temperature for 2-3 minutes, add the reaction solution to 250 mL of 0.4% PVA aqueous solution, adjust the stirring speed to 400 rpm, and stir at room temperature for about 4 hours until the DCM evaporates.

[0201] (4) Transfer the reaction solution to a 50 mL centrifuge tube, centrifuge (2500 rpm, 4 min), discard the supernatant, add 10 mL of deionized water and mix well by blowing, centrifuge and wash 3 times; finally add 5 mL of deionized water to resuspend, and obtain a milky white suspension of PLGA microspheres, which is stored in a 4℃ refrigerator for later use.

[0202] The PLGA microspheres were characterized using the following methods:

[0203] One drop of the milky white suspension of PLGA microspheres was placed on a silicon wafer and allowed to air dry at room temperature. The microspheres were then surface-sprayed with gold. The morphology of the prepared microspheres was characterized using a scanning electron microscope (SEM). The particle size distribution of the PLGA microspheres was detected and analyzed using a laser particle size analyzer.

[0204] Characterization results:

[0205] With other conditions kept constant, PLGA microspheres prepared from two PLGA polymers with different molecular weights (GA:LA = 75:25, MW: 4000-15000; or GA:LA = 50:50, MW: 50000-115000) were all milky white particles. The particle size distribution of the two types of microspheres was determined using a Malvem laser particle size analyzer. The particle size analysis results showed that the microspheres prepared from the PLGA polymer with GA:LA = 75:25 and MW: 4000-15000 had a particle size of approximately 33 μm. Figure 1 a) Microspheres prepared by GA∶LA=50∶50 and MW:50000-115000 have a particle size of approximately 77 μm. Figure 1 b). The morphology of the prepared microspheres was characterized by scanning electron microscopy. SEM results showed that both types of PLGA microspheres had smooth, spherical structures, were uniform in size, and exhibited good dispersibility; the microspheres prepared from the PLGA polymer with the lower molecular weight had smaller particle size. Figure 1 c) Microspheres prepared from PLGA polymers with high molecular weight have large particle sizes. Figure 1 d). Since the microsphere particle size range required for radioembolization therapy of liver cancer is 15-50 μm, this invention uses PLGA polymer with specifications of GA∶LA=75∶25 and MW:4000-15000 to prepare the microspheres required for subsequent experiments.

[0206] Example 3: Preparation and Characterization of PLGA@PDA Microspheres

[0207] The PDA shell layer was coated onto the surface of PLGA microspheres, and the specific method is as follows:

[0208] (1) Prepare a 10mM Tris-HCl aqueous solution by weighing 605.7mg Tris and dissolving it in 500mL of deionized water, measuring the pH value of the solution with a pH meter, and adding 1mM HCl to adjust the pH of the solution to about 8.5.

[0209] (2) The PLGA microsphere suspension prepared in Example 2 was freeze-dried into dry powder using a freeze dryer. 10 mg of PLGA microspheres were weighed and dissolved in 40 mL of Tris-HCl buffer solution (10 mM, pH = 8.5) to obtain microsphere suspension. A total of 4 microsphere suspensions were prepared.

[0210] (3) Weigh 10 mg, 20 mg, 30 mg and 40 mg of dopamine hydrochloride according to the mass ratio of PLGA microspheres to dopamine (DA) of 1:1, 1:2, 1:3 and 1:4 respectively, and add them to the above PLGA microsphere suspension. Stir at low speed (500 rpm) at room temperature for 1 h.

[0211] (4) Transfer the reaction solution to a 50 mL centrifuge tube, centrifuge (2000 rpm, 3 min), discard the supernatant, add 10 mL of deionized water and mix by blowing, centrifuge and wash 3 times, and finally add 1 mL of deionized water to resuspend, to obtain PLGA@PDA microsphere suspensions prepared according to different feed ratios (PLGA microspheres:DA), and store them in a 4℃ refrigerator for later use.

[0212] The PLGA@PDA microspheres were characterized using the following methods:

[0213] The prepared PLGA@PDA microsphere suspension was diluted to an appropriate concentration, and a drop of the solution was placed on a silicon wafer. The wafer was then allowed to air dry at room temperature, sputtered with gold, and the morphology of the PLGA@PDA microspheres was characterized using SEM. The C, N, and O elemental contents of the PLGA microspheres and PLGA@PDA microspheres were analyzed using X-ray photoelectron spectroscopy (XPS).

[0214] To determine the stability of the PDA coating on the surface of PLGA@PDA microspheres, microspheres modified with different feed ratios were placed at room temperature and their solution conditions were observed to determine the optimal modification conditions.

[0215] Further energy dispersive spectroscopy (EDS) was used to scan and analyze the C, N, and O elements of PLGA microspheres and PLGA@PDA microspheres;

[0216] The thickness of the PDA coating on the surface of PLGA@PDA microspheres was detected by XPS depth profiling. A total of 5 layers were etched, and the thickness of the PDA coating was determined by the content of nitrogen element.

[0217] The particle size distribution of PLGA@PDA microspheres was detected using a laser particle size analyzer.

[0218] Characterization results:

[0219] When PDA was coated onto the surface of PLGA microspheres, after adding dopamine to the PLGA microsphere suspension for 2-3 minutes, the reaction solution changed from an initial milky white to a light brown. As the reaction time increased, the color of the reaction solution gradually deepened, turning black after more than 20 minutes. After stirring at room temperature for 1 hour, PLGA@PDA microspheres with different mass ratios were obtained by centrifugation purification; all were black particles. The morphology of each group of PDA-coated microspheres was characterized using SEM. Figure 2SEM results showed that the PLGA@PDA microspheres prepared with different feed ratios were all spherical. Compared with the uncoated microspheres, the surface of the PLGA@PDA microspheres became uneven, but the PLGA@PDA microspheres still had good dispersibility and uniformity. The particle size did not change significantly and remained at around 30 μm, which meets the particle size requirements of liver cancer embolization microspheres.

[0220] PLGA microspheres are composed of three chemical elements: C, O, and H. Dopamine, in addition to these three elements, also contains the characteristic element N. Therefore, XPS was used to detect the C, N, and O content of PLGA and PLGA@PDA microspheres. XPS spectra of PLGA@PDA microspheres prepared with different feed ratios are shown below. Figure 3 a) The results show that the surface of all PLGA@PDA microspheres contains nitrogen (N). Only carbon (C) and oxygen (O) were detected on the PLGA microspheres. Figure 3 b). From the statistical results of N elements, we can see that ( Figure 3 c) When the PLGA microspheres:DA feed ratio (mass ratio) was 1:1, the nitrogen content was 1.26%; when the feed ratios were 1:2, 1:3, and 1:4, the nitrogen contents were 2.56%, 3.67%, and 4.75%, respectively; the nitrogen content gradually increased with the increase of the dopamine feed ratio. XPS detection results showed that the PLGA@PDA microspheres were successfully prepared.

[0221] The final reaction ratio (mass ratio) of PLGA microspheres to DA was determined by testing the stability of PLGA@PDA microspheres. The prepared microsphere suspension was placed at room temperature and photographed after one week. Figure 4 Microsphere suspensions prepared at feed ratios of 1:3 and 1:4, after standing at room temperature (25℃) for one week, showed that the microspheres settled at the bottom of the EP tube, and the upper layer of solution turned brown. In contrast, the upper layer of the microsphere suspensions prepared at feed ratios of 1:1 and 1:2 remained colorless and transparent. Based on these results, it can be inferred that when the feed ratios are 1:4 and 1:3, the PDA coating on the surface of the PLGA@PDA microspheres is relatively thick, which may lead to coating detachment and poor stability after prolonged exposure to solution. Considering that subsequent experiments require modification of the PDA coating, a PLGA microsphere:DA feed ratio (mass ratio) of 1:2 was used to prepare PLGA@PDA microspheres. The higher nitrogen content indicates a higher PDA content and better stability, which is beneficial for subsequent secondary modification. Therefore, subsequent experiments used a PLGA microsphere:DA mass ratio of 1:2.

[0222] EDS was used to analyze the C, N, and O elements in the microspheres, further confirming the microstructure and surface elemental distribution of the PLGA@PDA microspheres (prepared from PLGA microspheres:DA at a mass ratio of 1:2). The EDS results show that... Figure 5a) No nitrogen (N) was detected on the PLGA microspheres, but a uniform distribution of N was detected on the surface of the PLGA@PDA microspheres prepared after PDA modification. To determine the thickness of the PDA coating on the PLGA@PDA microsphere surface, XPS depth profiling was used for qualitative and quantitative analysis of the N element in the etched layer. The thickness of the PDA layer was determined by observing the decrease in N content from the surface of the PLGA@PDA microspheres to none during the etching process. Figure 5 b indicates that when etching reached the third layer (10nm per layer), no nitrogen (N) element, a characteristic element of the PDA coating, was detected. Therefore, it is inferred that the thickness of the PDA layer on the PLGA@PDA microsphere surface is between 20-30nm. The statistical results of the N element content in each layer show that... Figure 5 c) The nitrogen (N) content decreased with increasing etching layer number; no N characteristic element was detected in the PDA coating after etching to the third layer. Finally, the particle size distribution of the PLGA@PDA microspheres was analyzed. Figure 5 As can be seen from d, the particle size of PLGA@PDA microspheres is approximately 33 μm. Compared with PLGA microspheres, the particle size of PLGA@PDA microspheres did not change significantly, and the particle size distribution range was narrower, which meets the requirements for microsphere particle size in radioembolization therapy.

[0223] Example 4: Preparation and characterization of PLGA@PDA-Tz-I microspheres

[0224] Tz0, Tz1, Tz2, and Tz3 represent compounds 7, 9, 11, and 13, respectively. These four tetrazine compounds were used to modify PLGA@PDA microspheres. The tetrazine compound that grafted the most onto the surface of the PLGA@PDA microspheres after the reaction was used to prepare PLGA@PDA-Tz-I microspheres. The specific experimental procedures are as follows:

[0225] (1) Take 4 portions of 15mg PLGA@PDA microspheres and dissolve them in 2-3mL of deionized water to obtain PLGA@PDA microsphere suspension;

[0226] (2) Weigh 30 mg of Tz0-Tz3 compounds according to the mass ratio of PLGA@PDA microspheres to Tz compounds of 1:2, dissolve them in 20 mL of water to obtain tetrazine aqueous solution;

[0227] (3) Add tetrazine aqueous solution to PLGA@PDA microsphere suspension while stirring continuously, add appropriate amount of ammonia aqueous solution dropwise, adjust the pH of the reaction solution to 9-10, and stir at room temperature (500 rpm) for 12 h.

[0228] (4) Transfer the reaction solution to a 50 mL centrifuge tube, centrifuge (2000 rpm, 3 min), discard the supernatant, add 10 mL of deionized water and mix by blowing and washing, centrifuge and wash 3 times to obtain light reddish-brown PLGA@PDA-Tz-I microspheres, finally add 2 mL of deionized water to resuspend, and store in a 4℃ refrigerator for later use.

[0229] The PLGA@PDA-Tz-I microspheres were characterized using the following methods:

[0230] The prepared PLGA@PDA-Tz-I microspheres were diluted by a certain factor, and their morphology, dispersibility and uniformity were observed by SEM scanning.

[0231] XPS analysis was used to determine the percentage content of iodine, a characteristic element on the tetrazine molecule, and to detect the tetrazine that could be grafted onto the surface of the microspheres after modification. The microspheres prepared with this tetrazine molecule were used as non-radioactive PLGA@PDA-Tz-I microspheres.

[0232] Further analysis of the content and distribution of the four elements C, N, O and I in PLGA@PDA-Tz-I microspheres using EDS was conducted to corroborate the XPS data.

[0233] The presence of tetrazine molecules on the surface of PLGA@PDA-Tz-I microspheres with bioorthogonal reactivity was detected by reacting with a TCO-Cy5.5 probe. The specific procedure is as follows:

[0234] Take 0.1 mg of PLGA@PDA microspheres and PLGA@PDA-Tz-I microspheres respectively, and suspend them in 2 mL of deionized water; add 1 μL (5 mM) TCO-Cy5.5 to each, and react at room temperature for 45 min; centrifuge (2500 rpm, 4 min) to discard excess fluorescent probe, and then centrifuge and wash 3 times for purification; finally, suspend the microspheres in 1 mL of water, take one drop and put it on a glass slide, place it at room temperature to dry completely, and perform fluorescence imaging.

[0235] Characterization results:

[0236] Tetraazine compounds Tz0, Tz1, Tz2, and Tz3 (compounds 7, 9, 11, and 13, respectively) were added to the PLGA@PDA suspension, and the reaction solution turned red. After the reaction was complete, the solution was purified by centrifugation to obtain light reddish-brown PLGA@PDA-Tz-I microspheres. As shown in Example 3, the PLGA@PDA microspheres are composed of four elements: C, N, O, and H. When tetraazine compounds are modified onto the PDA layer on the surface of the microspheres, the characteristic element -I from the tetraazine small molecule is introduced. XPS detection results of the microspheres show that... Figure 6a) Compared with PLGA@PDA microspheres, the PLGA@PDA-Tz-I microspheres prepared after modification with tetrazine compounds all contained characteristic peaks of iodine. Experimental results showed that all four tetrazine molecules could be grafted onto the surface of PLGA@PDA microspheres through the reaction of the terminal amino groups with the benzoquinone groups of the PDA coating. Statistical results of iodine content in the four types of PLGA@PDA-Tz-I microspheres indicate that… Figure 6 (b) The iodine content in the microspheres prepared from Tz0 was 0.19%; the iodine content in the microspheres prepared from Tz1, Tz2, and Tz3 was 0.59%, 1.50%, and 0.66%, respectively. The experimental results show that Tz0 without PEG chain modification had the lowest grafting rate; while compound Tz2 with five PEG chains had the highest grafting rate. Therefore, Tz2 (compound 11) will be used to prepare non-radioactive PLGA@PDA-Tz-I microspheres for subsequent research. EDS results indicate that iodine is uniformly distributed on the surface of the PLGA@PDA-Tz-I microspheres. Figure 6 c).

[0237] The results of PLGA@PDA microsphere imaging show that ( Figure 7 a) No fluorescence signal was detected in the Cy5.5 fluorescence channel, indicating that the PLGA@PDA microspheres do not contain functional groups that can react with the TCO-Cy5.5 fluorescent probe. Under the same experimental conditions, the fluorescence imaging results of the PLGA@PDA-Tz-I microspheres show that ( Figure 7 (b) A fluorescence signal was detected in the Cy5.5 channel, and the Cy5.5 fluorescence signal was uniformly distributed on the microsphere surface. The microsphere fluorescence imaging results indicate that the tetrazine molecules, after being grafted onto the microsphere surface, still possess the ability to undergo a bioorthogonal reaction with TCO.

[0238] Example 5: Study on in vitro degradation of PLGA@PDA-Tz-I microspheres

[0239] Currently, all microspheres used clinically for TARE in liver cancer are non-biodegradable. Ideally, embolization microspheres should be stable in the physiological environment during treatment and degrade in vivo after treatment. This invention assesses the biodegradability of PLGA@PDA-Tz-I microspheres by detecting morphological changes over 0-120 days in a medium containing 10% FBS, using SEM for detection. The experimental methods are as follows:

[0240] (1) Weigh about 0.1 mg of PLGA@PDA-Tz-I microspheres (prepared from compound 11) dry powder, dissolve it in 2 mL of DMEM medium containing 10% FBS, and prepare a microsphere suspension;

[0241] (2) Place the microsphere suspension at room temperature (23-25℃) and replace it with fresh culture medium every two days. Take an appropriate amount of microspheres on days 0, 15, 30, 60, 90 and 120 respectively, and perform SEM scanning to observe the morphology and structure of the microspheres and understand their stability and biodegradability in in vitro culture medium containing 10% FBS.

[0242] result:

[0243] The stability and degradability of the microspheres in cell culture medium containing 10% FBS were tested. SEM scan results showed that... Figure 8 The microspheres were initially placed in 10% FBS cell culture medium (day 0). The microspheres were spherical and intact, exhibiting an uneven surface due to modification. From day 15, subtle changes in the surface morphology of the microspheres began to appear, with a small number showing surface coating cracking. After 30 days at room temperature, most microspheres began to show surface cracking. By day 60, the internal structure of the microspheres also showed signs of lysis, with pores of varying sizes appearing. Furthermore, with prolonged exposure, chemically degradable sensitive bonds (such as lipid bonds) in the main chain were exposed, making them more susceptible to hydrolysis. By day 90, the porosity further increased, and the microsphere skeletal structure began to collapse, losing its spherical shape. By day 120, the PLGA@PDA-Tz-I microspheres were completely degraded in serum, forming amorphous polymers. The experimental results indicate that the microspheres showed good morphology in the early stages in 10% FBS culture medium, but after day 90, the spherical structure began to degrade rapidly. The results show that the embolic microspheres prepared in this invention can be completely degraded in 10% FBS culture medium and can be degraded in vivo after the treatment is completed.

[0244] Example 6: Radiolabeling of compound 25 with gallium-68

[0245] Under hydrochloric acid and sodium acetate conditions, 50 μg of compound 25 was dissolved in 400 μL of 0.1 M hydrochloric acid eluent containing gallium-68. Then, 160 μL of 1 N sodium acetate aqueous solution was added to the reaction system. After the addition was complete, the reaction was carried out at 90 °C for 20 min. The radioactive gallium-68 in the reaction system was chelated using the EDTA structure of compound 25. After the reaction was completed, a sample was taken for HPLC analysis, and the results are as follows: Figure 9 As shown. The synthetic route for gallium-68 labeling is as follows:

[0246]

[0247] From the experimental results of high performance liquid chromatography (HPLC) Figure 9It is evident that compounds like compound 25, containing EDTA and a tetrazine structure, can successfully label radioactive gallium-68. Therefore, following the method described in this paper, radioactive microspheres containing different nuclides, such as gallium-68, can be prepared. This further expands the diversity and practicality of this type of radioactive microsphere.

[0248] Example 7, PLGA@PDA-Tz- 131 Preparation of I-microspheres

[0249] 1. Iodine-131 labeled tetrazine small molecules

[0250] The labeling of radioactive iodine-131 tetrazine small molecules was performed using an electrophilic substitution reaction. Under acidic conditions, N-iodosuccinimide (NIS) oxidized iodide anions to electrophilically active radioactive iodine, which then underwent an electrophilic substitution reaction with the trimethyltin group on the benzene ring of compound 14, thereby preparing iodine-131 labeled tetrazine small molecule 17. After the reaction was completed, the reaction was quenched using sodium citrate. The reaction equation and specific operation method for iodine-131 labeled tetrazine are as follows:

[0251]

[0252] (1) Solution preparation: Weigh 80 mg NIS, dissolve in 2 mL methanol solution, and serially dilute to a concentration of 0.4 mg / mL; weigh 160 mg sodium ascorbate, dissolve in 2 mL deionized water, and serially dilute to a concentration of 0.8 mg / mL; take 10 mg compound 14, dissolve in 1 mL DCM solution, dilute 10 times, and prepare a 1 mg / mL tetrazine solution;

[0253] (2) Take 5 μL Na 131 I solution (325 μCi) was placed in a 3 mL EP tube; 8 μL of glacial acetic acid, 8 μL of NIS methanol solution, and 6.5 μL of compound 14 DCM solution were added sequentially; the mixture was vortexed and allowed to react at room temperature for 25-30 min.

[0254] (3) Add 8 μL of sodium ascorbate solution and vortex to mix and terminate the reaction;

[0255] (4) Take 2 μL of the reaction solution and dilute it to 20 μL with acetonitrile. Monitor the radioactive product (compound 17) using HPLC and perform integration processing on the γ-HPLC peak. Figure 10 The labeling yield of iodine-131 on compound 14 was detected, and the radiolabeling rate of iodine-131 on tetrazine was found to be 92.89%.

[0256] 2. PLGA@PDA-Tz- 131 Preparation of I-microspheres

[0257] (1) Solution preparation: 0.4 mg / mL NIS (methanol solution); 0.8 mg / mL sodium ascorbate (aqueous solution); 1 mg / mL compound 14 (DCM solution);

[0258] (2) Take 55 μL Na 131 I total 5.0 mCi; 60 μL glacial acetic acid, 60 μL NIS solution, and 100 μL compound 14 solution were added sequentially; after vortexing and mixing, the mixture was reacted at room temperature for 40 min;

[0259] (3) Add 60 μL of sodium ascorbate solution and vortex to mix and terminate the reaction;

[0260] (4) Add 50 μL of DCM extract 17 and detect the radioactivity of the DCM solution;

[0261] (5) Add 40 μL of TFA deamination protecting group (i.e., Boc protecting group) to DCM, react at room temperature for 2 h, and check the reaction is complete using TCL; the reaction equation is as follows:

[0262]

[0263] (6) Add 200 μL of deionized water to extract the final product (compound 18) three times and detect the radioactivity.

[0264] (7) Add 5-7 mL of deionized water to (6) to dilute, and then add an appropriate amount of ammonia to adjust the pH to between 8 and 9;

[0265] (8) Add 0.1 mL of PLGA@PDA microspheres to (7), and the microsphere density is approximately 1.1 × 10⁻⁶ as determined by flow cytometry. 7 -1.5×10 7 The reaction was carried out at room temperature with stirring for 15 hours, with the concentration of cells / mL.

[0266] (9) Microsphere purification: Centrifuge (2000 rpm, 4 min), wash 3 times to obtain PLGA@PDA-Tz- 131 I. Radioactive microspheres were used to detect the radioactivity of the microspheres; the radioactive microsphere preparation experiment was repeated three times to calculate the iodine-131 labeling efficiency of the microspheres.

[0267] Test results:

[0268] Table 1 shows the radiochemical yield (RCY) of each step in the preparation of radioactive microspheres from tetrazine iodine-131 labeling. The overall yield of radioactive microspheres is approximately 50%.

[0269] Table 1. PLGA@PDA-Tz- 131 Labeling rates of each reaction step in the preparation of I microspheres

[0270]

[0271]

[0272] Example 8: In vivo stability study of PLGA@PDA-Tz-I microspheres via hepatic artery embolization

[0273] To assess the stability of the microspheres in vivo, PLGA@PDA-Tz-I microspheres (non-radioactive microspheres) were used for hepatic artery embolization in rats (normal rats). The microspheres were injected into the hepatic artery, and their morphology and structure in the hepatic vessels were observed at different time points to determine whether the embolization microspheres could achieve complete embolization in the liver, whether they could remain stable during the treatment period, and whether they could block the blood supply to the liver tumor. The specific procedures are as follows:

[0274] (1) Preoperative preparation: The rats were fasted for 24 hours before the operation and were deprived of water for 6 hours before the operation;

[0275] (2) The gas anesthesia conditions for rats during the operation were: a mixture of 5% isoflurane and 95% oxygen. The rats were placed supine in a sterile medical animal surgical drape. Throughout the operation, the rats were given gas anesthesia to keep them in a state of deep anesthesia.

[0276] (3) Use a hair clipper to shave the hair off the rat's abdomen, wipe the abdominal skin with an alcohol swab, and disinfect before the operation.

[0277] (4) Open the abdominal cavity along the xiphoid process of the rat's sternum, and use sterile surgical scissors to cut an incision of about 3-5 cm along the linea alba of the rat's abdomen to expose the liver tissue;

[0278] (5) Use a sterile cotton swab to open the liver tissue, find the common hepatic artery, hepatic artery and gastroduodenal artery, separate the hepatic artery from the portal vein, and insert a sterile 5-0 surgical suture at the distal end of the hepatic artery and the duodenal artery respectively.

[0279] (6) Find a suitable injection site, lift the surgical suture, cut off the blood supply to the stomach and liver arteries, and use a 1mL insulin needle to slowly and evenly inject the microspheres along the direction of hepatic artery blood flow (hepatic artery into liver). Remove the syringe and use a sterile cotton swab to press the injection site to stop bleeding.

[0280] (7) After the hepatic artery blood flow stops, the abdominal wound is sutured (the muscle layer and the epidermis are sutured separately to prevent the surgical suture from breaking and the wound from reopening). Finally, the skin around the wound is disinfected with an alcohol swab and erythromycin ointment is applied to prevent postoperative infection.

[0281] (8) Remove the anesthesia device, put the rat back into the cage with sterile bedding, and after the rat wakes up, put it back into the animal room to continue feeding.

[0282] (9) On day 7 and day 30, liver tissue samples were taken from rats and sections were prepared to observe the blockage of blood vessels by microspheres in the liver.

[0283] result:

[0284] Imaging results of rat liver tissue sections after arterial microsphere embolization showed that the embolization effect lasted for 7 days ( Figure 11 a) and 30 days ( Figure 11 (b) In the experimental group, scattered embolic microspheres were clearly observed within the hepatic blood vessels. These microspheres did not adhere to each other and maintained their spherical shape without significant deformation. The images clearly show that the microspheres blocked the capillary network of the hepatic artery and could effectively disrupt the tumor's blood supply for an extended period.

[0285] Example 9, PLGA@PDA-Tz- 131 In vivo stability study of I microspheres

[0286] Ideally, radioembolization microspheres should not only possess structural stability but also prevent the therapeutic radionuclide from easily detaching from the microspheres in vivo. Before TARE treatment in model mice, PLGA@PDA-Tz- was tested. 131 The stability of the PLGA@PDA-Tz microspheres (prepared in Example 7) in vivo was assessed using SPECT / CT fusion imaging to monitor their distribution and determine their stability. 131 The stability of the microspheres (prepared in Example 7) in the liver was assessed. The specific experimental procedures are as follows:

[0287] (1) Six rats with primary liver cancer were randomly divided into two groups of three. One group was injected with 120 μL (500 μCi) PLGA@PDA-Tz- via hepatic artery embolization. 131 I microspheres, another group injected with the same dose of Na 131 I. Physiological saline; All experimental rats were fasted for 24 hours and deprived of water for 6 hours before the operation. The specific surgical procedure is as described in Example 8.

[0288] (2) After administration via the hepatic artery, PLGA@PDA-Tz- 131 I microsphere experimental group and Na 131 The control group underwent SEPCT / CT fusion imaging to monitor PLGA@PDA-Tz- 131 I distribution in vivo, evaluating PLGA@PDA-Tz- 131 In vivo stability of the I-microspheres. SPECT / CT imaging parameters are as follows:

[0289] First, a CT localization scan was performed with the following parameters: tube voltage 100kV, tube current 10mAs. After acquiring the localization image, the scanning area was delineated on it, and a thin-slice CT scan was performed with the following parameters: tube current 100kV, tube current 80mAs / 90mAs, slice thickness 0.625mm, matrix 512×512, and scanning field of view 12cm. After the CT images were acquired, the SPECT images were acquired. The SPECT was equipped with a high-energy collimator, and the gamma probe acquired a main energy peak of 364Kev with a window width of 20%. A scattering peak was added for scattering correction, with a scattering peak of 297Kev and a window width of 20%. The matrix was 128×128, the magnification was 1.0, and one frame was acquired every 6 degrees of rotation, with each frame acquired for 15 seconds. A dual-probe 360-degree acquisition process (each probe rotated 180 degrees) was used, for a total of 30 frames. The entire imaging process took 11-14 minutes. After image acquisition, image processing is performed on the image post-processing workstation, mainly including image fusion, window width and window level, background color levels, etc.

[0290] Methods for preparing the model rats: A liver cancer animal model was established using female SD rats. Before drug-induced liver cancer modeling, the rats were housed in the animal facility of West China Clinical Science and Technology Park, Sichuan University for one week to acclimatize to the environment. During the first week of drug induction, 0.05‰ DEN (25 μL DEN / 500 mL drinking water) was used as the inducer; starting from the second week, 0.1‰ DEN (50 μL DEN / 500 mL drinking water) was used as the inducer. Drug administration was continuous throughout the entire drug induction process, with the inducer changed three times per week for a total of eight weeks. All animal experimental procedures were approved by the Animal Ethics Committee of Sichuan University and strictly followed the standard regulations for animal experiments, adhering to the 3R animal welfare principles during the experiment.

[0291] result:

[0292] The distribution of iodine-131 in vivo was monitored using SPECT / CT fusion imaging in rats. Figure 12 From a, we can know that PLGA@PDA-Tz- 131 In the microsphere experimental group, SPECT / CT scans from days 3 to 60 post-surgery showed that iodine-131 was consistently distributed in the liver tissue, while no significant distribution of iodine-131 was detected in other organs (especially the thyroid gland, which has specific iodine uptake). (From Na...) 131 The SPECT / CT imaging results of experimental group I show that ( Figure 12 (b) On postoperative day 3, free iodine-131 was mostly distributed in the thyroid gland, with smaller amounts distributed in the liver, kidneys, and bladder; by day 14, all iodine-131 was metabolized and excreted from the body, leaving almost no iodine-131 signal in the body. In summary, PLGA@PDA-Tz- 131The microspheres exhibit good traceability, and their distribution in vivo can be monitored using SPECT / CT imaging. SPECT / CT fusion imaging results show that the microspheres did not undergo significant deiodination in vivo, indicating good in vivo stability. Experimental results demonstrate that PLGA@PDA-Tz- 131 I-microspheres exhibit high stability in vivo up to 60 days prior and have the potential for TARE treatment of liver cancer.

[0293] Example 10, PLGA@PDA-Tz- 131 Results of studies on the use of I-microspheres in liver cancer treatment

[0294] To evaluate PLGA@PDA-Tz- 131 The efficacy of transarterial radioembolization of microspheres combined with click-release drug delivery for the treatment of in situ hepatocellular carcinoma was investigated. Thirty-six rats with hepatocellular carcinoma were prepared according to the method described in Example 9 and randomly divided into six groups (n=6 per group):

[0295] Group A: PLGA@PDA-Tz- 131 I / TCO-Mitomycin C combination therapy group, group B: PLGA@PDA-Tz- 131 Group I: Treatment group; Group C: PLGA@PDA-Tz-I / TCO-Mitomycin C combined treatment group; Group D: PLGA@PDA-Tz-I treatment group; Group E: TCO-Mitomycin C prodrug group (compound 16); Group F: Sham surgery group.

[0296] 1. Dosing regimens for rats in each experimental group

[0297] (1) In two experimental groups, A and B, each model mouse was injected with approximately 500 μCi (500,000-600,000 radioactive microspheres) via the hepatic artery; after the radioactive embolization microspheres were administered via the hepatic artery, the average absorbed dose D in normal liver tissue was... live r The formula for calculating (Gy / kg) is shown in Equation I. The S value is the activity-radiation dose conversion coefficient, and the S value of iodine-131 is 14.8.

[0298]

[0299] Vega et al. investigated 188 After administering Re-labeled microspheres to rats via the hepatic artery, the maximum radiation absorbed dose in normal rat liver tissue was calculated to be approximately 20 Gy. In this invention, the dosage administered to each model rat was 500 μCi, and the rat liver mass was approximately 12 g. The D calculated according to Formula I... liverThe value was approximately 22.8 Gy / kg, which is basically consistent with the average absorbed dose of normal liver tissue reported in the literature. Therefore, the dosage of 500 μCi of radioactive embolization microspheres injected into each rat via the hepatic artery is reasonable.

[0300] (2) In experimental groups C and D, each model mouse was injected with 500,000-600,000 PLGA@PDA-Tz-I microspheres via the hepatic artery;

[0301] (3) Experimental groups A, C, and E containing TCO-Mitomycin C prodrug: TCO-Mitomycin C was dissolved in physiological saline and administered via tail vein injection. The drug was administered once every two days for two consecutive weeks. Each model mouse was given a dose of 5 mg / kg.

[0302] (4) Group F received a total volume of 125 μL of physiological saline via the hepatic artery.

[0303] 2. Evaluation of therapeutic effects in rats of each experimental group

[0304] The efficacy was evaluated mainly through the following three aspects: MR imaging of rat liver tumors, the trend of tumor volume growth over time, and survival rate.

[0305] Rat liver tumor MRI: Since the two days following surgery are considered the perioperative period, anesthesia and imaging procedures are not recommended. The first MRI scan was performed on the third postoperative day, followed by MRI scans every seven days for a total of four scans to monitor the growth of liver tumors in each experimental group. MRI was used to locate the liver in rats, and the orthotopic hepatocellular carcinoma model was established based on the MRI results. Rat MRI scans were performed using a rat-specific MRI coil (4-channel phased array abdominal coil). Animals were anesthetized with a gas mixture containing 5% isoflurane / 95% oxygen, and MRI was performed while the rats were under deep anesthesia. MRI scans were performed using T2-weighted imaging (T2WI). The main parameters of the MRI are as follows: repetition time (TR): 1517.59ms, echo time (TE): 23.00ms, field of view (FOV): 60.00mm×60.00mm, matrix: 225×250, spatial resolution: 0.313mm×0.313mm×1.0mm, slice thickness: 1.0mm, interslice spacing: 0.18mm, number of slices: 20, bandwidth: 300Hz, scan time: 146s.

[0306] Tumor volume and proliferation trend: The tumor volume of the liver was statistically analyzed using MR imaging, and a tumor growth curve was plotted. The tumor volume was calculated using the Tada formula, as shown in Equation II:

[0307] V = a × b × c × π / 6 (Equation II)

[0308] a: Longest diameter of the slice with the largest tumor area (mm); b: Longest vertical diameter of a (mm); c: Number of tumor slices appearing on MRI (mm).

[0309] Survival curves: While monitoring tumor growth, the survival time of each group of experimental mice was recorded, the survival rate of each group of rats was calculated, and survival curves were plotted.

[0310] result:

[0311] The MRI monitoring results of each experimental group show that ( Figure 13 In group A, tumor growth was well inhibited in the early stages. After two weeks of treatment, the tumor area shrank significantly, and by the third week, the tumor had completely disappeared. In group B, the tumor gradually shrank during treatment but was not completely eliminated, and the treatment effect was not as good as in group A. The experimental results of groups A and B show that TARE combined with click-release drug has a better therapeutic effect. In group C, tumor growth was slow in the first two weeks of treatment, but after 14 days, it showed a significant growth trend, indicating that PLGA@PDA-Tz-I can inhibit tumor growth by releasing the active drug Mitomycin C in situ, but chemotherapy alone cannot achieve the goal of tumor elimination. In group D, the treatment results were similar to those of group B in the early stages, but from day 7, the tumor gradually grew, and by day 21, the tumor growth trend had become uncontrollable, accompanied by tumor metastasis. This may be because the microspheres inhibited the growth of liver tumors to a certain extent in the early stages of treatment by blocking the tumor blood supply. However, simply blocking the tumor blood supply cannot achieve the goal of tumor treatment. With the growth of the tumor, new blood vessels are formed, which can provide nutrients for tumor growth. In rats of groups E and F, after 7 days of drug administration, the primary liver tumors showed a significant growth trend, accompanied by liver tumor metastasis. After 14 days, both the primary and metastatic tumors had significantly increased in size. The experimental results indicate that groups A and B have a good inhibitory effect on tumor growth, with group A (PLGA@PDA-Tz-) showing the best results. 131 The I / TCO-Mitomycin C combination therapy group can achieve the combined treatment of TARE and click-release by releasing the original drug Mitomycin C at the tumor site, thereby achieving the goal of completely eliminating the tumor and demonstrating excellent tumor-suppressing effects.

[0312] Trends in liver tumor volume changes in rats of each treatment group ( Figure 14In Group A, tumor volume showed no significant difference in the first 7 days of treatment. Starting on day 14, tumor volume began to decrease, shrinking by approximately 70% by day 21. In Group B, tumor volume showed no significant difference in the first 14 days of treatment, but increased approximately tenfold by day 21. Tumor volume statistics further demonstrate that combined treatment is more effective than radioembolization alone. In Groups C and D, tumor volume did not change significantly in the first 7 days, but showed a significant increasing trend later. In Groups E and F, liver tumor volume consistently increased over time. The experimental results further demonstrate that in Group A, PLGA@PDA-Tz- 131 Transarterial embolization combined with click-release response-modulated chemotherapy can control liver tumor growth and metastasis, achieving effective treatment for liver cancer.

[0313] The statistical results of the survival time of rats in each group show that ( Figure 15 The median survival times for groups E, D, and F were 23 days, 20 days, and 19 days, respectively, with no significant difference among these three groups. However, the median survival times for groups C and B were 31 days and 39 days, respectively, significantly higher than those for groups D, E, and F. The improved median survival in group C was attributed to the click-release reaction between the TCO-Mitomycin C prodrug and PLGA@PDA-Tz-I at the tumor site, releasing the active drug Mitomycin C to disinfect cancer cells and inhibit tumor growth. Group B achieved its anti-tumor effect by blocking tumor blood supply and releasing β-rays from iodine-131. Survival statistics showed that the survival times for groups F, E, D, and C were 30, 44, 41, and 52 days, respectively. Survival statistics for group F indicated rapid disease progression and a short survival time in rats with liver cancer. Although the survival times for groups C, D, and E were all higher than that of group F, all rats in these groups died within 8 weeks post-surgery, failing to achieve the desired therapeutic effect. Compared to the sham surgery group, group B had a survival time extended by approximately 40 days, demonstrating that PLGA@PDA-Tz- 131 I-microspheres have a certain therapeutic effect on liver cancer. Compared with the sham-operated group, the survival time of group A was prolonged by 50 days, further improving the survival time of rats, demonstrating that PLGA@PDA-Tz- 131 I-microsphere transarterial embolization combined with click-release response-regulated chemotherapy for the treatment of rats with orthotopic liver cancer can achieve good therapeutic effects and significantly improve the survival time of the liver cancer model mice, which is a promising combination therapy strategy for liver cancer.

[0314] Example 11, PLGA@PDA-Tz- 131 Study on the effect of microsphere embolization on liver function in rats

[0315] Studies have reported that liver function is affected shortly after TARE surgery, with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) being the most sensitive biochemical indicators of hepatocyte damage. Therefore, in the early stages of treatment, the serum ALT and AST levels of rats in each experimental group were monitored. Three rats were randomly selected from each group, and blood was collected periodically from the tail vein after drug administration (Note: all experimental rats were fasted and deprived of water for 4 hours before blood collection). The blood was centrifuged at low temperature (10,000 rpm, 10 min), and the supernatant serum was collected and stored at -80℃ for later use. Blood collection time points were 1 day before surgery and on days 1, 2, 3, 7, and 15 post-surgery. The experimental procedures for AST and ALT detection are as follows:

[0316] ALT detection - colorimetric method:

[0317] (1) Add 10 μL of rat serum from the experimental group to the test tube, then add 0.5 mL of alanine aminotransferase matrix solution, mix well by pipetting, and incubate at 37°C for 30 min; add 0.5 mL of alanine aminotransferase matrix solution to the control tube.

[0318] (2) Add 50 μL of 2,4-dinitrophenylhydrazine solution to the test tube and the control tube; mix well by blowing and incubate in a water bath at 37°C for 20 min;

[0319] (3) Add 50 μL of NaOH (0.4 mol / L) solution to the control tube and the test tube respectively, mix well by blowing and incubating at room temperature for 5 min, and zero the absorbance at 505 nm with deionized water. Detect the absorbance value of each tube, and after conversion (absolute OD value = OD value of test tube - OD value of control tube), find the corresponding ALT / GPT activity units from the standard curve.

[0320] (4) Statistical analysis of the test results and plotting the ALT change curve over time were performed to analyze the effect of each group on the liver function-related enzyme ALT in rats after administration.

[0321] AST detection - colorimetric method:

[0322] (1) Add 10 μL of serum from the experimental group rats to the test tube, then add 50 μL of aspartate aminotransferase matrix solution, mix well by pipetting, and incubate at 37℃ for 30 min; add 50 μL of aspartate aminotransferase matrix solution to the control tube.

[0323] (2) Add 50 μL of 2,4-dinitrophenylhydrazine solution to the test tube and the control tube; mix well by blowing and incubate in a water bath at 37°C for 20 min;

[0324] (3) Add 50 μL NaOH (0.4 mol / L) to the control tube and the test tube respectively, mix well by blowing, incubate at room temperature for 5 min, use deionized water to zero at 505 nm, detect the absorbance value of each tube, and after conversion (absolute OD value = test tube OD value - control tube OD value), find the corresponding AST / GPT activity units from the standard curve.

[0325] (4) Organize the test results and draw the AST change curve over time to analyze the effect of each group on the liver function-related enzyme AST after administration.

[0326] In normal rats, serum ALT levels ranged from 28 to 75 U / L, and AST levels ranged from 125 to 225 U / L. Liver function test results for each group of rats are as follows: Figure 16 In group E, ALT and AST levels remained within the normal range. In group AD, the trends of ALT and AST changes were consistent after 3 days of treatment, showing an increase followed by a decrease. In group F, AST and ALT showed the same trend as the other treatment groups after treatment, but the maximum increase in both enzymes was lower than the other four groups; on day 1 after treatment, ALT increased by 0.8 times and AST increased by 0.3 times. After one week, there were no statistically significant differences in ALT and AST among the groups, and they eventually returned to normal levels. The experimental results indicate that the embolization treatment of liver cancer model rats in this invention will cause liver function damage in the short term (3 days post-surgery), but the expression of AST and ALT in the liver can return to normal levels one week after surgery, and it does not cause irreversible damage to the vital signs of the rats throughout the treatment process.

[0327] Example 12: Pathological analysis of major organs in rats of each group

[0328] The heart, spleen, lungs, and kidneys of rats in each group were sampled, sectioned, and stained with H&E. The images were then taken under an optical microscope to observe any morphological changes in the organs during the treatment process.

[0329] result:

[0330] Pathological examinations were performed on the major organs (excluding liver tissue) of rats in each experimental group. The H&E staining results of the tissue sections from the major organs of each group of rats showed that... Figure 17 No obvious tissue damage was observed in any of the major organs, with no obvious edema, shrinkage, necrosis, or other abnormal morphology. The organs in each group maintained their complete morphology and structure, and clear cell structures and nuclei morphology were observed. These results further demonstrate that the PLGA@PDA-Tz synthesized in this invention... 131 I-microspheres have high biocompatibility in vivo, and the treatment regimen has a high degree of safety, without causing significant toxic side effects.

[0331] This invention first successfully synthesized PLGA microspheres with a particle size of approximately 30 μm. A PDA coating was then applied to the surface of the microspheres. Using the PDA coating as a secondary modification platform, iodine-131-labeled tetrazine small molecules (Tz-) were introduced. 131 I, compound 18), successfully prepared PLGA@PDA-Tz- 131 I. Microspheres. The microspheres, after two modifications, exhibit intact sphericity, good dispersibility, uniform particle size, and no adhesion. In vitro and in vivo stability experiments both demonstrate that the microspheres possess good stability against radioactive iodine-131. Furthermore, through a bioorthogonal click-release reaction between tetrazine and TCO, drug release can be achieved in situ within the tumor, utilizing chemotherapy drugs to kill cancer cells. PLGA@PDA-Tz- 131 I, a novel microsphere with therapeutic capabilities for iodine-131 and click-release properties, enables combined TARE and chemotherapy treatment for liver cancer. This combined therapy strategy offers a potential treatment option for patients with intermediate to advanced liver cancer.

[0332] The present invention achieves the following beneficial effects:

[0333] (1) A tetrazine precursor compound 14 for iodine-131 labeling was synthesized through a four-step reaction; iodine-131 was successfully labeled by electrophilic substitution to obtain iodine-131 labeled tetrazine compound 17; the Boc protecting group was further deaminated to obtain compound 18 with a terminal amino group; the secondary amine functional group of Mitomycin C was modified to prepare TCO-Mitomycin C prodrug (compound 16).

[0334] (2) PLGA microspheres suitable for hepatic artery embolization were prepared using an emulsion crosslinking method. PDA was then coated onto the surface of the microspheres, successfully modifying the PLGA microspheres. Compound 18 was further grafted onto the PDA coating surface to prepare a novel radioactive PLGA@PDA-Tz- 131 I. Embolization microspheres, in which the tetrazine small molecule can achieve click release of the active drug Mitomycin C in the prodrug TCO-Mitomycin C (compound 16);

[0335] (3)PLGA@PDA-Tz- 131 I-microspheres exhibit high stability in vivo. By monitoring the distribution of microspheres in vivo using SPECT / CT imaging, they can stably embolize hepatic arteries for up to 60 days.

[0336] (4) The TARE-tetraazine click-release strategy has shown good anti-tumor effects and can be used as an effective treatment strategy for unresectable intermediate and advanced liver cancer.

[0337] In summary, this invention provides biodegradable PLGA@PDA microspheres grafted with tetrazine compounds, which can treat cancer, particularly liver cancer. When the tetrazine compounds on the microspheres contain radioactive elements, they can be used for radioembolization therapy, achieving internal radiation therapy for liver cancer. Furthermore, the tetrazine compounds grafted onto the microspheres can simultaneously perform radioembolization therapy and utilize a click-release reaction to release chemotherapeutic drugs in situ from the tumor, achieving local click-release of drugs. The microspheres of this invention can organically combine internal radiation therapy and click-release, effectively inhibiting the growth and metastasis of liver tumors, providing a new approach for the combined treatment of liver cancer, and have broad application prospects.

Claims

1. A microsphere, characterized in that: It is a polylactic acid-glycolic acid copolymer microsphere with a polydopamine shell on its surface; the polydopamine shell is grafted with a tetrazine compound; The polylactic acid-glycolic acid copolymer microspheres are prepared by using polylactic acid-glycolic acid copolymer as raw material through an emulsification crosslinking method; The structure of the tetrazine compound is shown in Formula I: Formula I in, n is an integer selected from 0 to 10; R1 is selected from substituted or unsubstituted 6-10 aryl groups. Therefore, the substituents of the aryl group are selected from I, 131 I, ; a is an integer selected from 0 to 3; R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements; R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively. R2 is selected from hydrogen, , ; b is an integer selected from 1 to 8; R8 is selected from hydrogen.

2. The microspheres according to claim 1, characterized in that: n is an integer selected from 0 to 3; R1 is selected from substituted or unsubstituted phenyl groups. Therefore, the substituents of the phenyl group are selected from I, 131 I, ; a is an integer selected from 0 to 3; R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements; R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively. R2 is selected from hydrogen, , ; b is an integer selected from 1 to 5; R8 is selected from hydrogen.

3. The microspheres according to claim 1, characterized in that: The structure of the tetrazine compound is shown in Formula II: Formula II in, n is an integer selected from 0 to 3; R1 is selected from substituted or unsubstituted phenyl groups. Therefore, the substituents of the phenyl group are selected from I, 131 I, ; a is an integer selected from 0 to 3; R3 and R4 are independently selected from... The Chelated or non-chelated radioactive elements; R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively. b is an integer selected from 1 to 5; R8 is selected from hydrogen.

4. The microspheres according to claim 3, characterized in that: The structure of the tetrazine compound is shown in Formula III: Formula III in, n is an integer selected from 0 to 3; R9 is selected from hydrogen, I, 131 I, ; R4 is selected from The The radioactive element may or may not be chelated; the radioactive element is gallium-68 or yttrium-90. R5, R6, and R7 are each independently selected from hydrogen, C1-C8 alkyl, carboxyl, hydroxyl, amino, nitro, and halogen, respectively. b is an integer selected from 1 to 5; R8 is selected from hydrogen; Alternatively, the structure of the tetrazine compound is shown in Formula V: Formula V in n is an integer selected from 0 to 3; b is an integer selected from 1 to 5; The compound shown in Formula V may or may not chelate a radioactive element; the radioactive element is gallium-68 or yttrium-90.

5. The microspheres according to claim 4, characterized in that: The structure of the tetrazine compound is shown in Formula VI: Style VI in b is an integer from 1 to 5.

6. The microspheres according to claim 1, characterized in that: The structure of the tetrazine compound is one of the following compounds: 、 、 、 、 、 、 、 。 7. The microspheres according to claim 1, characterized in that: The polylactic acid-glycolic acid copolymer is a polylactic acid-glycolic acid copolymer with GA:LA = 75:25 and MW: 4000-15000.

8. The microspheres according to claim 1, characterized in that: The preparation method of the polylactic acid glycolic acid copolymer microspheres coated with a polydopamine shell includes the following steps: reacting polylactic acid glycolic acid copolymer microspheres with dopamine in a solvent to obtain the microspheres.

9. The microspheres according to claim 8, characterized in that: The mass ratio of the polylactic acid-glycolic acid copolymer microspheres to dopamine is 1:(1~4). And / or, the solvent is an aqueous solution of Tris-HCl; And / or, the reaction is carried out at room temperature with stirring at 100-1000 rpm for 1-5 h.

10. The microspheres according to claim 9, characterized in that: The mass ratio of the polylactic acid-glycolic acid copolymer microspheres to dopamine is 1:2; And / or, the concentration of the Tris-HCl aqueous solution is 10 mM and the pH is 8-9; And / or, the reaction is carried out at room temperature with stirring at 500 rpm for 1 h; And / or, the reaction is purified, and the purification method is to centrifuge the reaction solution, discard the supernatant, wash, and freeze-dry.

11. The microspheres according to claim 1, characterized in that: The preparation method of the polylactic acid-glycolic acid copolymer microspheres includes the following steps: (1) Dissolve the polylactic acid-glycolic acid copolymer in an organic solvent to obtain an organic solution of the polylactic acid-glycolic acid copolymer; (2) Dissolve the crosslinking agent in an aqueous solution to obtain a crosslinking agent solution; (3) Add the polylactic acid-hydroxyacetic acid copolymer organic solution dropwise to the crosslinking agent solution and stir to react, and the product is obtained.

12. The microspheres according to claim 11, characterized in that: In step (1), the organic solvent is DCM; And / or, in step (1), the concentration of the polylactic acid-glycolic acid copolymer organic solution is 1-5%; And / or, in step (2), the crosslinking agent is polyvinyl alcohol; And / or, in step (2), the concentration of the crosslinking agent solution is 0.4~1.0%; And / or, in step (3), the crosslinking agent solution is stirred during the dropwise addition. And / or, in step (3), the reaction temperature is room temperature; And / or, in step (3), the reaction is purified by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

13. The microspheres according to claim 1, characterized in that: The method for branching tetrazine compounds onto a polydopamine shell includes the following steps: 1) Dissolve PLGA@PDA microspheres in water to obtain a PLGA@PDA microsphere suspension; 2) Dissolve tetrazine compounds in water to obtain tetrazine aqueous solutions; 3) Add the tetrazine aqueous solution to the PLGA@PDA microsphere suspension and react to obtain the product; the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:(1~5).

14. The microspheres according to claim 13, characterized in that: In step 3), the pH of the reaction solution is 9-10 during the reaction. And / or, in step 3), the reaction is carried out at room temperature for 10-20 hours; And / or, in step 3), the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:2; And / or, in step 3), the post-reaction purification is carried out by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

15. A method for preparing the microspheres according to any one of claims 1 to 14, characterized in that: It includes the following steps: 1) Dissolve PLGA@PDA microspheres in water to obtain a PLGA@PDA microsphere suspension; 2) Dissolve tetrazine compounds in water to obtain tetrazine aqueous solutions; 3) Add the tetrazine aqueous solution to the PLGA@PDA microsphere suspension and react to obtain the product; the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:(1~5).

16. The method according to claim 15, characterized in that: In step 3), the pH of the reaction solution is 9-10 during the reaction. And / or, in step 3), the reaction is carried out at room temperature for 10-20 hours; And / or, in step 3), the mass ratio of the PLGA@PDA microspheres to the tetrazine compound is 1:2; And / or, in step 3), the post-reaction purification is carried out by centrifuging the reaction solution, discarding the supernatant, washing, and lyophilizing.

17. Use of the microspheres according to any one of claims 1 to 14 in the preparation of a medicament for treating cancer.

18. The use according to claim 17, characterized in that: The cancer in question is liver cancer.

19. The use according to claim 18, characterized in that: The liver cancer mentioned is primary liver cancer.

20. Use of the microspheres according to any one of claims 1 to 14 in combination with mitomycin C prodrug in the preparation of a medicament for treating cancer; wherein the structure of mitomycin C is as follows: 。 21. The use according to claim 20, characterized in that: The cancer in question is liver cancer.

22. The use according to claim 21, characterized in that: The liver cancer mentioned is primary liver cancer.

Citation Information

Patent Citations

  • Bio-orthogonal drug activation

    CN103732256A